Emmaus Life Sciences (NASDAQ:EMMA) versus BioRestorative Therapies (NASDAQ:BRTX) Critical Analysis

Emmaus Life Sciences (NASDAQ:EMMA) and BioRestorative Therapies (OTCMKTS:BRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Risk and Volatility

Emmaus Life Sciences has a beta of 2.86, meaning that its share price is 186% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.


This table compares Emmaus Life Sciences and BioRestorative Therapies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Emmaus Life Sciences -561.61% -467.46% -216.02%
BioRestorative Therapies -11,481.82% N/A -1,063.30%

Insider & Institutional Ownership

2.5% of Emmaus Life Sciences shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by insiders. Comparatively, 25.8% of BioRestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Emmaus Life Sciences and BioRestorative Therapies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Emmaus Life Sciences 0 0 0 0 N/A
BioRestorative Therapies 0 0 0 0 N/A

Valuation and Earnings

This table compares Emmaus Life Sciences and BioRestorative Therapies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Emmaus Life Sciences $1.32 million 143.83 -$9.59 million ($11.16) -0.36
BioRestorative Therapies $110,000.00 44.89 -$12.52 million N/A N/A

Emmaus Life Sciences has higher revenue and earnings than BioRestorative Therapies.


Emmaus Life Sciences beats BioRestorative Therapies on 8 of the 9 factors compared between the two stocks.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.